Different mechanisms for resistance to trastuzumab versus lapatinib in HER2- positive breast cancers -- role of estrogen receptor and HER2 reactivation

INTRODUCTION: The human epidermal growth factor receptor 2 (HER2)-targeted therapies trastuzumab (T) and lapatinib (L) show high efficacy in patients with HER2-positive breast cancer, but resistance is prevalent. Here we investigate resistance mechanisms to each drug alone, or to their combination u...

Full description

Saved in:

Bibliographic Details
Main Authors:	Wang, Yen-Chao, Morrison, Gladys, Gillihan, Ryan, Guo, Jun, Ward, Robin M, Fu, Xiaoyong, Botero, Maria F, Healy, Nuala A, Hilsenbeck, Susan G, Phillips, Gail Lewis, Chamness, Gary C, Rimawi, Mothaffar F, Osborne, C Kent, Schiff, Rachel
Format:	Artigo
Language:	Inglês
Published:	BioMed Central 2011
Subjects:	Research Article
Online Access:	https://ncbi.nlm.nih.gov/pmc/articles/PMC3326563/ https://ncbi.nlm.nih.gov/pubmed/22123186 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/bcr3067
Tags:	Add Tag No Tags, Be the first to tag this record!

Different mechanisms for resistance to trastuzumab versus lapatinib in HER2- positive breast cancers -- role of estrogen receptor and HER2 reactivation

Similar Items